In this article
Pfizer
on Thursday said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial.
Patients with obesity or who are overweight lost up to 12.3% of their weight compared with placebo at week 28 in the ongoing phase two study. The injection’s weight loss was up to 10.5% when analyzing all patients regardless of discontinuations.
The company said no plateau was observed after patients transitioned to monthly dosing, which suggests that continued weight loss is expected as the study continues through week 64.
